The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Coding variants in TREM2 increase risk for Alzheimer's disease
Open accessAbstract
The triggering receptor expressed on myeloid 2 (TREM2) is an immune phagocytic receptor expressed on brain microglia known to trigger phagocytosis and regulate the inflammatory response. Homozygous mutations in TREM2 cause Nasu-Hakola disease, a rare recessive form of dementia. A heterozygous TREM2 variant, p.R47H, was recently shown to increase Alzheimer''s disease (AD) risk. We hypothesized that if TREM2 is truly an AD risk gene, there would be additional rare variants in TREM2 that substantially affect AD risk. To test this hypothesis, we performed pooled sequencing of TREM2 coding regions in 2082 AD cases and 1648 cognitively normal elderly controls of European American descent. We identified 16 non-synonymous variants, six of which were not identified in previous AD studies. Two variants, p.R47H [P = 9.17 × 10(-4), odds ratio (OR) = 2.63 (1.44-4.81)] and p.R62H [P = 2.36 × 10(-4), OR = 2.36 (1.47-3.80)] were significantly associated with disease risk in single-variant analyses. Gene-based tests demonstrate variants in TREM2 are genome-wide significantly associated with AD [PSKAT-O = 5.37 × 10(-7); OR = 2.55 (1.80-3.67)]. The association of TREM2 variants with AD is still highly significant after excluding p.R47H [PSKAT-O = 7.72 × 10(-5); OR = 2.47 (1.62-3.87)], indicating that additional TREM2 variants affect AD risk. Genotyping in available family members of probands suggested that p.R47H (P = 4.65 × 10(-2)) and p.R62H (P = 6.87 × 10(-3)) were more frequently seen in AD cases versus controls within these families. Gel electrophoresis analysis confirms that at least three TREM2 transcripts are expressed in human brains, including one encoding a soluble form of TREM2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous TREM2 mutations linked with AD have been identified, including R47H, R62H, N68K, D87N, T96K, and so on.191,193”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [191]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with these enrichment analyses, both rare and common variants have been identified in core microglial genes, such as TREM213,14.”
From Variant-to-function mapping of late-onset Alzheimer’s disease GWAS signals in human microglial cell models implicates RTFDC1 at the CASS4 locus (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Homozygous mutations are associated with Nasu–Hakola disease (NHD),189 or frontotemporal dementia,190 while the TREM2 variants associates with AD are heterozygous.191”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [191]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, TREM2 variants associate with an increased risk of AD [15, 25, 38–40].”
From Protective PLCG2 variants associate with a delayed onset of Alzheimer’s disease among heterozygous APOE ε4 carriers (2026) · cites this paper as [40]
The cited source says what the claim attributes to it.
In the citing paper
“supporting a strong immunological role in AD93–95 including TREM27,96, CD33, and IL34.”
From Proteogenomic analysis of human cerebrospinal fluid identifies neurologically relevant regulation and implicates causal proteins for Alzheimer’s disease (2024) · cites this paper as [96]
In the citing paper
“Several other TREM2 variants that affect the expression of TREM2 also increased the risk of AD, including R62H, T66M, H157Y, and D87N.”
From Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets (2023) · cites this paper as [166]
In the citing paper
“Since the identification of R47H, additional rare variants in TREM2 have been associated with AD risk [138–140]”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [139]
In the citing paper
“The risk from this variant has a comparable effect size with the APOEε4 allele (around 3-fold increased AD risk; 4,19–22).”
From Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions (2020) · cites this paper as [20]
In the citing paper
“In addition to the R47H variant, further TREM2 variants have been revealed to be risk factors of AD or other CNS diseases, such as R62H (8,20), H157Y (25), Q33X, T66M and Y38C (26,27).”
From Trem2 promotes anti-inflammatory responses in microglia and is suppressed under pro-inflammatory conditions (2020) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Self-citationVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Rare-Variant Association Testing for Sequencing Data with the Sequence Kernel Association Test
Wu, M. C., Lee, S., Cai, T., Li, Y., Boehnke, M., & Lin, X. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.05.029 · Cited by 2,373
Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., et al. (1994) · Nature Genetics · doi:10.1038/ng0694-180 · Cited by 1,920
Flagged first, then by citations
Research works printed but not linked: 6
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1569
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1568
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1565
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1565
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1568
- 2013, TREM2 and neurodegenerative disease, N. Engl. J. Med., 369, 1567
Cited by
Sorted by citations
Items 301–315 of 315
Villegas-Llerena, C., Paredes-Moscosso, S. R., Guevara, M. L., Obispo, D., Custodio, N., Montesinos, R., Parodi, J. F., Flores-Flores, O., Hardy, J., & Fujita, R. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1724380
Marqueurs périphériques de l'inflammation et déclin cognitif au cours de la maladie d'Alzheimer
Julian, A. (2018) · theses.fr (ABES) · doi:10.70675/0f58e0a1z28d9z40b7z886fz752caf42c261
Abdelouahab, O. B. (2021) · theses.fr (ABES) · doi:10.70675/97f4885fz3f5cz4234zb8e2ze3fa7c4e3d41
Hemonnot-Girard, A.-L. (2021) · theses.fr (ABES) · doi:10.70675/9c8a4775zd774z494ez9bbazf7566faefa8f
Lietzke, E. E., Saeb, D., Aldrich, E. C., de Menezes, R. F., Bruce, K. D., & Sprenger, K. G. (2026) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2026.06.002 · Cited by 1
Oloruntimehin, E. S., & Malogolovkin, A. S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135668
Wu, X., Zhang, Y., Yang, Q., Xue, L., Guo, Y., Li, L., Liu, C., Jin, M., Pan, G., Men, J., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70567
Wang, H., Wen, R., Parker, E., & Yang, L. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-03083-9 · Cited by 2
Yang, G., Xu, X., & Xu, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1893545
Kuhnau, L., Jimenez, G. A., Hack, W. R., Varada, S., Gladen-Kolarsky, N., Kim, S., Klein, F., Banerji, T., Quinn, J. F., Scanlan, T. S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.31.741838
Decoding TREM2: A microglial receptor governing the fate of myelin
Zhang, Z., Zhang, W., Jin, L., Wei, C., Chen, H., 程相树, & Wei, J. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112815
Chen, M., Zuo, C., Li, R., Zhang, J., Yao, Z., Li, L., & Cheng, L. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00314-0
The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective
Çataklı, D., Özen, Ö., Tuncgovde, E. B., & Ozsarlak‐Sozer, G. (2026) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70294
Expression predictions inform molecular interpretation of Alzheimer’s disease risk lociPreprint
hyug, C. B., & Jeong, J. (2026) · medRxiv · doi:10.64898/2026.10.07.26364928 · Cited by 1
Tan, Q., Xie, A., Chen, J., Wei, S., Guo, Y., Liu, G., Wang, L., Liu, X., & 杜艳军 (2026) · Research Square · doi:10.21203/rs.3.rs-11138446/v1
Metadata
- Authors
- Jin, S. C., Benitez, B. A., Karch, C. M., Cooper, B., Skorupa, T., Carrell, D., Norton, J. B., Hsu, S., Harari, O., Cai, Y., Bertelsen, S., Goate, A. M., & Cruchaga, C.
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- Goate, Alison M.
- Cruchaga, Carlos
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-06-04
- Volume
- 23
- Issue
- 21
- Pages
- 5838-5846
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC4189899
- OpenAlex
- W2107590165
- Cited by
- 314
- References
- 46
- Citations by year
- 2026: 20 · 2025: 34 · 2024: 28 · 2023: 18 · 2022: 23 · 2021: 31 · 2020: 30 · 2019: 28 · 2018: 30 · 2017: 27 · 2016: 23 · 2015: 18 · 2014: 4
- FWCI
- 16.00
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Molecular Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Federation for Aging Research
- Alvin J. Siteman Cancer Center (CA91842, #P30 CA91842)
- Georgia Clinical and Translational Science Alliance (UL1TR000448)
- National Institutes of Health (NIH P50, UL1TR000448, 5p30ns069329-02, AG05681, AG 03991, CA91842, NS069329)
- National Institute on Aging (RF1AG044546, AG03991, K01AG046374, AG 05681, R01AG035083, U24 AG21886, P 50 AG05681, R01AG041797, R01AG044546, AG026276, P50AG005681, P01 AG0 3991, P01AG003991, AG035083, U24AG026395, U24AG056270, P01AG026276, U24AG021886)
- National Cancer Institute (P30 CA 91842, CA91842, P30CA091842)
- National Institute of Neurological Disorders and Stroke (P30-NS069329)
- National Center for Research Resources (P30 CA91842)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- TREM2, Alzheimer's disease, genetic risk variants, microglia, non-synonymous variants, Nasu-Hakola disease, soluble TREM2, gene-based association, European-American population
- MeSH terms
- Adult, Aged, Aged, 80 and over, Alzheimer Disease, Amino Acid Sequence, Brain, Female, Humans, Male, Membrane Glycoproteins, Middle Aged, Molecular Sequence Data, Receptors, Immunologic, Risk, Genetic Variation, Case-Control Studies, Open Reading Frames, Sequence Alignment, Alternative Splicing, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Genetic Association Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
